Dear PES Members, As a dual US and Canadian citizen, I admit that I find these times particularly sad and…
Read MoreMore Articles
These resources have been identified by members as being useful during these difficult times. They are provided as a reference only. Timely information about COVID-19 that is curated specifically for…
Read More
Riomet ER™ (metformin hydrochloride for extended-release oral suspension) was approved by the U.S. Food and Drug Administration (USFDA) on August 29, 2019 and became available in the US at the…
Read More
In December 2019, the FDA announced approval of Tandem Diabetes Care Control-IQ™ Technology. Control-IQ Technology on the t:slim X2™ insulin pump can adjust basal insulin delivery and deliver automated correction…
Read More
Fiasp (Novo Nordisk) is a faster insulin aspart with an earlier onset of action. In contrast to NovoLog, which is recommended to be dosed within 5-10 minutes before meals, Fiasp may be dosed immediately…
Read More
In response to findings of a safety signal report that there is reasonable suspicion of a causal association between use of Increlex® and childhood neoplasia, including malignancy, changes have been made…
Read More
The FDA has approved two new ready to use forms of glucagon and these have been introduced to the market: an intranasal powder (Baqsimi, Eli Lilly) and a stable liquid…
Read More
Vitamin D is a fat soluble vitamin that is essential for maintaining bone health and also has other potential health benefits. While some of these other health benefits are not…
Read More
Levothyroxine sodium oral solution (Tirosint-SOL) has now been approved by the FDA and is available for use in the US. Please click on the link below for details regarding the product…
Read More
Overview
The FDA recently approved a Safety Labeling Change (SLC) addressing the risk of necrolytic migratory erythema (NME) with continuous intravenous glucagon use. This change has been made because of case reports of NME, including three pediatric and three adult cases. All of the pediatric cases were also reported to the FDA Adverse Event Reporting System (FAERS). The first citation below contains two of the pediatric cases. One adult case (Mullans, et al.) was only available from the literature; the other two adult cases were also reported to FAERS. The FDA does not know the incidence of NME nor the incidence of off-label use of glucagon.
For the full wording of the label change, please log in.
Not a member?